[Whitepaper] Funding Treatments for Rare Diseases- PPI
At the WODC meeting in Washington on April 20 2016, PPi HC will be chairing a full day event on the important topic of funding treatments for rare diseases. This very sensitive area is a greatly contentious one, and so we are very proud to bring together a highly prestigious payer panel consisting of experts and payers from the US, UK, France, Italy, Australia and Bulgaria.
Download white paper now
Concessions and incentives to support the development of ODs include the following, but there are many countries where such concessions do not extend to payer decision-making on pricing and reimbursement (P&R), including Health Technology Assessment (HTA).
Extended market exclusivity (7-10 years)
Tax and fee reductions (clinical trials, inspections, MAs)
Protocol assistance, free advice
Research grants
Central European filing / expedited regulatory review
Single format annual report to either FDA or EMA
We are thrilled to announce that PPi Healthcare Consulting are joining us as a sponsor at this year’s World Orphan Drug Congress USA 2016. Register today to meet them in D.C. on April 20-22.